We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+11.29%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$244M
AUM Growth
+$29.9M
Cap. Flow
+$6.34M
Cap. Flow %
2.6%
Top 10 Hldgs %
46.31%
Holding
78
New
4
Increased
21
Reduced
24
Closed
3

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$3.4M
2
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$2.69M
3
BLUE
bluebird bio
BLUE
+$2.63M
4
ZGNX
Zogenix, Inc.
ZGNX
+$2.06M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.85M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$2.23M
2
NERV icon
Minerva Neurosciences
NERV
+$977K
3
LMNX
Luminex Corp
LMNX
+$945K
4
LRMR icon
Larimar Therapeutics
LRMR
+$784K
5
ATRC icon
AtriCure
ATRC
+$684K

Sector Composition

Rank Sector Weight
1 Healthcare 88.76%
2 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHN
26
DELISTED
Achillion Pharmaceuticals
ACHN
$3.12M 1.28%
847,636
-100,000
-11% -$298K
YARW
27
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$3.07M 1.26%
87
– –
INDP icon
28
Indaptus Therapeutics
INDP
$172M
$3.03M 1.25%
240
-14
-6% -$133K
BEAT
29
DELISTED
BioTelemetry, Inc.
BEAT
$3.02M 1.24%
46,800
-7,700
-14% -$430K
BLUE
30
DELISTED
bluebird bio
BLUE
$2.99M 1.23%
1,583
+1,274
+412% +$2.63M
TVRD
31
Tvardi Therapeutics
TVRD
$19.7M
$2.7M 1.11%
3,134
+1,389
+80% +$1M
AGTC
32
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.63M 1.08%
359,860
-61,140
-15% -$268K
ARQL
33
DELISTED
Arqule Inc
ARQL
$2.53M 1.04%
447,664
+259,000
+137% +$1.47M
WVE icon
34
Wave Life Sciences
WVE
$1.09B
$2.4M 0.98%
47,900
– –
VBIV
35
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$2.26M 0.93%
31,156
– –
CSII
36
DELISTED
Cardiovascular Systems, Inc.
CSII
$2.2M 0.9%
56,200
-3,000
-5% -$111K
ARDX icon
37
Ardelyx
ARDX
$1.22B
$2.06M 0.84%
472,859
– –
DRNA
38
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.81M 0.74%
118,500
+8,500
+8% +$124K
MGNX icon
39
MacroGenics
MGNX
$235M
$1.68M 0.69%
78,305
– –
ADXS
40
DELISTED
Advaxis Inc
ADXS
$1.57M 0.64%
111,111
+64,644
+139% +$1.26M
SCYX icon
41
SCYNEXIS
SCYX
$48.1M
$1.53M 0.63%
15,912
-32
-0.2% -$3.78K
TBIO
42
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$1.52M 0.62%
151,739
+131,739
+659% +$1.53M
INCY icon
43
Incyte
INCY
$24.2B
$1.49M 0.61%
21,500
– –
NTUS
44
DELISTED
Natus Medical Inc
NTUS
$1.35M 0.55%
37,900
– –
NVAX icon
45
Novavax
NVAX
$1.2B
$1.32M 0.54%
35,000
-2,500
-7% -$70.4K
JNJ icon
46
Johnson & Johnson
JNJ
$618B
$1.3M 0.53%
9,400
– –
IMDZ
47
DELISTED
Immune Design Corp.
IMDZ
$1.13M 0.47%
328,500
– –
BHVN
48
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.13M 0.46%
30,000
+6,500
+28% +$239K
CYPH
49
Cypherpunk Technologies Inc
CYPH
$62.9M
$1.1M 0.45%
14,064
-1,100
-7% -$82.1K
LRMR icon
50
Larimar Therapeutics
LRMR
$397M
$1M 0.41%
7,154
-6,461
-47% -$784K
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, DAFNA Capital Management held 78 positions worth $244M, up 14% from $214M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management's Q3 2018 filing shows 4 new, 21 increased, 24 reduced and 3 closed positions. Its largest new stake was Spero Therapeutics: 70,000 shares worth $736K. The largest sale was DexCom, an estimated $2.23M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q3 2018 buy was Spero Therapeutics: 70,000 shares worth $736K.
  • DAFNA Capital Management added most to argenx in Q3 2018, an estimated $3.4M increase.
  • DAFNA Capital Management's biggest Q3 2018 reduction was DexCom, cutting an estimated $2.23M.
  • DAFNA Capital Management fully exited Galmed Pharmaceuticals in Q3 2018, selling an estimated $595K.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $244M portfolio in Q3 2018.
  • DAFNA Capital Management opened 4 new positions and closed 3 in Q3 2018.
  • DAFNA Capital Management's portfolio value rose 14% quarter-over-quarter to $244M.

Based on DAFNA Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.